Literature DB >> 192429

Renal vein plasma adenosine 3',5'-cyclic monophosphate in renovascular hypertension.

O Kuchel, F H Messerli, G Tolis, P Hamet, J Fraysse, P Cartier, P Roy, R Boucher, J Genest.   

Abstract

The concentration of plasma adenosine 3',5'-cyclic monophosphate (cyclic AMP) and plasma renin activity (PRA) were measured concomitantly in blood from both renal veins and in arterial blood in 22 hypertensive patients. In the nine patients with true renovascular hypertension the concentration of plasma cyclic AMP was greater in the venous effluent of the kidney affected by the renal artery stenosis than in that of the unaffected or less affected kidney. The arteriovenous difference in cyclic AMP concentration was less on the affected side in all but one patient. The arteriovenous differences in PRA identified the affected kidney as the source of hyper-reninemia and showed that renin release from the other kidney was suppressed. In the 13 patients with hypertension associated with but unrelated to renal artery stenosis there were no consistent patterns of cyclic AMP concentration or PRA in the venous effluent of the kidneys or of their arteriovenous differences. In renovascular hypertension the venous effluent of the kidney affected by renal artery stenosis contains not only more renin but also more cyclic AMP, owing to either increased cyclic AMP production or decreased excretion or extraction of cyclic AMP by the affected kidney. This unilateral increase in cyclic AMP concentration may become a complementary diagnostic feature of true renovascular hypertension.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 192429      PMCID: PMC1879045     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  12 in total

1.  NEW PROCEDURES FOR MEASUREMENT OF HUMAN PLASMA ANGIOTENSIN AND RENIN ACTIVITY LEVELS.

Authors:  R BOUCHER; R VEYRAT; J DE CHAMPLAIN; J GENEST
Journal:  Can Med Assoc J       Date:  1964-01-25       Impact factor: 8.262

2.  Catheter replacement of the needle in percutaneous arteriography; a new technique.

Authors:  S I SELDINGER
Journal:  Acta radiol       Date:  1953-05       Impact factor: 1.990

3.  Studies of the elevated extracellular concentration of cyclic AMP in uremic man.

Authors:  P Hamet; D A Stouder; H E Ginn; J G Hardman; G W Liddle
Journal:  J Clin Invest       Date:  1975-08       Impact factor: 14.808

4.  Catecholamine-dependent cyclic adenosine monophosphate and renin in the dog kidney.

Authors:  N Beck; K S Kim; B B Davies
Journal:  Circ Res       Date:  1975-03       Impact factor: 17.367

5.  [Excretion of cyclic AMP in arterial hypertension].

Authors:  P Hamet; O Kuchel; J Genest
Journal:  Union Med Can       Date:  1973-04

6.  Central vasomotor stimulation by angiotensin.

Authors:  C M Ferrario; C J Dickinson; J W McCubbin
Journal:  Clin Sci       Date:  1970-08       Impact factor: 6.124

7.  In vitro stimulation of renin production by epinephrine, norepinephrine, and cyclic AMP.

Authors:  A M Michelakis; J Caudle; G W Liddle
Journal:  Proc Soc Exp Biol Med       Date:  1969-03

8.  Plasma clearance rates and renal clearance of 3H-labeled cyclic AMP and 3H-labeled cyclic GMP in the dog.

Authors:  L Blonde; R E Wehmann; A L Steiner
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

9.  Plasma adenosine 3',5'-cyclic monophosphate in human hypertension.

Authors:  P Hamet; O Kuchel; J Fraysse; J Genest
Journal:  Can Med Assoc J       Date:  1974-08-17       Impact factor: 8.262

10.  A protein binding assay for adenosine 3':5'-cyclic monophosphate.

Authors:  A G Gilman
Journal:  Proc Natl Acad Sci U S A       Date:  1970-09       Impact factor: 11.205

View more
  1 in total

Review 1.  The impact of peptide hormone receptor research on clinical medicine.

Authors:  T F Davies
Journal:  J R Coll Physicians Lond       Date:  1978-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.